These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 921875)

  • 21. Evaluation of creatinine phosphokinase in screening patients for malignant hyperpyrexia.
    Ellis FR; Clarke IM; Modgill M; Currie S; Harriman DG
    Br Med J; 1975 Aug; 3(5982):511-3. PubMed ID: 1164612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia.
    Nelson TE
    J Clin Invest; 1983 Sep; 72(3):862-70. PubMed ID: 6886007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical studies on malignant hyperpyrexia.
    Pennington RJ; Worsfold M
    Proc R Soc Med; 1973 Jan; 66(1 Pt 1):69-70. PubMed ID: 4266079
    [No Abstract]   [Full Text] [Related]  

  • 24. Porcine malignant hyperthermia susceptibility: increased calcium-sequestering activity of skeletal muscle sarcoplasmic reticulum.
    O'Brien PJ
    Can J Vet Res; 1986 Jul; 50(3):329-37. PubMed ID: 3742368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland].
    Urwyler A; Censier K; Seeberger MD; Drewe J; Rothenbühler JM; Frei F
    Schweiz Med Wochenschr; 1991 Apr; 121(16):566-71. PubMed ID: 2042040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of procaine in the treatment of malignant hyperpyrexia.
    Clarke IM; Ellis FR
    Br J Anaesth; 1975 Jan; 47(1):17-21. PubMed ID: 1148070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for malignant hyperpyrexia.
    Ellis FR; Keaney NP; Harriman DG; Sumner DW; Kyei-Mensah K; Tyrrell JH; Hargreaves JB; Parikh RK; Mulrooney PL
    Br Med J; 1972 Sep; 3(5826):559-61. PubMed ID: 5069639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Porcine malignant hyperthermia: halothane effects on force generation in skeletal muscles.
    Gallant EM; Goettl VM
    Muscle Nerve; 1989 Jan; 12(1):56-63. PubMed ID: 2747737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triglycerides, not phospholipids, are the source of elevated free fatty acids in muscle from patients susceptible to malignant hyperthermia.
    Fletcher JE; Rosenberg H; Michaux K; Tripolitis L; Lizzo FH
    Eur J Anaesthesiol; 1989 Sep; 6(5):355-62. PubMed ID: 2792095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Procaine in malignant hyperpyrexia.
    Moulds RF; Denborough MA
    Br Med J; 1972 Dec; 4(5839):526-8. PubMed ID: 4642792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defective Mg2+ regulation of RyR1 as a causal factor in malignant hyperthermia.
    Steele DS; Duke AM
    Arch Biochem Biophys; 2007 Feb; 458(1):57-64. PubMed ID: 16620769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Divergent effects of the malignant hyperthermia-susceptible Arg(615)-->Cys mutation on the Ca(2+) and Mg(2+) dependence of the RyR1.
    Balog EM; Fruen BR; Shomer NH; Louis CF
    Biophys J; 2001 Oct; 81(4):2050-8. PubMed ID: 11566777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mg2+ dependence of Ca2+ release from the sarcoplasmic reticulum induced by sevoflurane or halothane in skeletal muscle from humans susceptible to malignant hyperthermia.
    Duke AM; Hopkins PM; Halsall PJ; Steele DS
    Br J Anaesth; 2006 Sep; 97(3):320-8. PubMed ID: 16849381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells.
    Girard T; Treves S; Censier K; Mueller CR; Zorzato F; Urwyler A
    Br J Anaesth; 2002 Oct; 89(4):571-9. PubMed ID: 12393358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphorus-31 nuclear magnetic resonance studies of muscle metabolism in malignant hyperpyrexia.
    Galloway GJ; Denborough MA
    Br J Anaesth; 1984 Jun; 56(6):663-4. PubMed ID: 6721975
    [No Abstract]   [Full Text] [Related]  

  • 36. [Ca2+]i in muscles of malignant hyperthermia susceptible pigs determined in vivo with Ca2+ selective microelectrodes.
    Lopez JR; Alamo LA; Jones DE; Papp L; Allen PD; Gergely J; Sréter FA
    Muscle Nerve; 1986 Jan; 9(1):85-6. PubMed ID: 3951486
    [No Abstract]   [Full Text] [Related]  

  • 37. Electrophoretic analysis of proteins in malignant hyperpyrexia susceptible skeletal muscle.
    Marjanen LA; Denborough MA
    Int J Biochem; 1984; 16(8):919-29. PubMed ID: 6468747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ca-induced Ca release in malignant hyperthermia-susceptible pig skeletal muscle.
    Ohta T; Endo M; Nakano T; Morohoshi Y; Wanikawa K; Ohga A
    Am J Physiol; 1989 Feb; 256(2 Pt 1):C358-67. PubMed ID: 2919663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microcalorimetric studies in malignant hyperpyrexia susceptible individuals.
    Ranklev E; Monti M; Fletcher R
    Br J Anaesth; 1985 Oct; 57(10):991-3. PubMed ID: 4041326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A halothane-induced biochemical defect in muscle of normal and malignant hyperthermia-susceptible Landrace pigs.
    Mitchell G; Heffron JJ; van Rensburg AJ
    Anesth Analg; 1980 Apr; 59(4):250-6. PubMed ID: 7189363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.